Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a broad range of severe diseases. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/16/20 | $45,000,000 | Series A |
Samsara BioCapital Versant Ventures  | undisclosed |
